Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZDP2
|
|||
| Drug Name |
TAK-573
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Refractory multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [2] | ||
| Company |
Takeda
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | . | [3] |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| WikiPathways | Oxytocin signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03215030) A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Takeda. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.